President Donald J. Trump has taken a significant step in U.S. drug and mental health policy by expanding federal support for psychedelic research and accelerating access to experimental treatments.
In an executive order signed in April 2026, Donald Trump directed federal agencies to speed up the development, review, and controlled use of psychedelic substances for medical purposes, particularly for serious mental health conditions such as post-traumatic stress disorder (PTSD), depression, and addiction. The move marks one of the most substantial federal shifts in decades toward legitimizing substances that have long been classified as illegal under U.S. law.
The order focuses on compounds including psilocybin, MDMA, LSD, and ibogaine, instructing the U.S. Food and Drug Administration to prioritize review pathways for therapies that have shown early clinical promise. It also expands the use of “Right to Try” provisions, allowing certain patients with severe or treatment-resistant conditions to access investigational psychedelic treatments outside standard approval timelines.
A major component of the policy includes approximately $50 million in federal funding to support research programs, with an emphasis on veterans’ mental health. The administration has highlighted rising rates of suicide and treatment resistance among veterans as a key justification for accelerating alternative therapeutic options.
The announcement comes amid growing scientific interest in psychedelics as potential psychiatric treatments. Early clinical trials have suggested that these substances, when administered in controlled medical settings alongside therapy, may help reduce symptoms of PTSD and depression in patients who do not respond to conventional medications. However, experts continue to stress that risks remain, including psychological distress during sessions and possible long-term side effects.
The policy has generated strong reactions across political and medical communities. Supporters argue it represents a long-overdue modernization of drug policy and an opportunity to address urgent mental health challenges. Critics, however, warn that evidence is still limited and caution against rapid expansion before larger-scale safety data is available.
This latest move signals a broader shift in federal attitudes toward psychedelic medicine, positioning the United States closer to countries such as Australia and Switzerland, where certain psychedelic therapies are already permitted in tightly regulated clinical environments.